Achromobacter: an emerging nosocomial pathogen
DOI:
https://doi.org/10.18203/2320-6012.ijrms20193400Keywords:
Achromobacter denitrificans, Achromobacter xylosoxidans, Antimicrobial drug resistance, Emerging pathogens, Nonfermenter, Nosocomial infectionAbstract
Background: Achromobacter is a ubiquitous, non-fermenting, Gram-negative bacterium that lives in soil and aquatic environments. In recent years, many studies have shown its potential as opportunistic pathogen. It can colonize various items used in hospital and can survive various disinfectants. The infections get complicated due to its vast spectrum of intrinsic and extrinsic resistance to antimicrobial agents and disinfectants. Achromobacter spp. is an emerging pathogen and is becoming a reservoir for horizontal genetic transfer elements involved in spreading antibiotic resistance. This study was conducted to assess the extent of the Achromobacter related infection in our hospital setting and to set a baseline for future studies.
Methods: This study was conducted over a period of one year (January to December 2018) in our tertiary care hospital. All specimens submitted for aerobic culture and sensitivity were analyzed and the bacterial identification and antibiotic sensitivity of the isolates was carried out using automated method (Vitek 2 Compact, bioMerieux).
Results: Achromobacter species was reported from 0.46% (63/13831) specimens, 40% of them were isolated from suction tips. Achromobacter denitrificans amounted for 47/63 (74.6%) while Achromobacter xylosoxidans was identified in 16/63 (25.4%).
Conclusions: Studying the organisms in order to observe their changing trendsReferences
Reverdy ME, Freney J, Fleurette J, Coulet M, Surgot M, Marmet D, et al. Nosocomial colonization and infection by Achromobacter xylosoxidans. J Clin Microbiol. 1984;19(2):140-3
Kumar A, Ray P, Kanwar M, Sethi S, Narang A. Investigation of hospital-acquired infections due to Achromobacter xylosoxidans in a tertiary care hospital in India. J Hosp Infect. 2006;62(2):248-50.
Yabuuchi E, Oyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol. 1971;15(5):477-81.
Yabuuchi E. Twenty-seven years with the nomenclature of Achromobacter xylosoxidans [in Japanese. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi. 1999;10(1):1-12.
Yabuuchi E, Kawamura Y, Kosako Y, Ezaki T. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (Packer and Vish¬niac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans subsp. denitrificans (Ruger and Tan) comb.Nov. Microbiol Immunol. 1998;42(6):429-38.
Weaver RE, Tatum HW, Hollis DG. The identification of unusual pathogenic gram-negative bacteria, U.S. Department of Health, Education and Welfare Center for Disease Control. Atlanta, Ga; 1978: 1-12.
Duggan JM, Goldstein SJ, Chenoweth CE, Kauffman CA, Bradley SF. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis. 1996; 23(3):569-76.
Gómez-Cerezo J, Suárez I, Ríos JJ, Peña P, García de Miguel MJ, de José M, et al. Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis. 2003;22(6):36-43.
Barragán EP, Pérez JS, Corbella L, Orellana MÁ, Fernández-Ruiz M. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Chemotherapist. 2018;31(3):268-73.
Chandrasekar PH, Arathoon E, Levine DP. Infections due to Achromobacter xylosoxidans: case report and review of the literature. Infection. 1986;14(6):279-82.
Spear JB, Fuhrer J, Kirby BD. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a well water source: case report and review of the literature. J Clin Microbiol. 1988;26(3):598-9.
Puthucheary SD, Ngeow YF. Infections with Achromobacter xylosoxidans. Singapore Med J. 1986;27:58-62.
Giacoia GP. Achromobacter xylosoxidans: A drug-resistant pathogen in newborns and immunocompromised patients. South Med J. 1990;83(11):1312-4.
Kidd TJ, Ramsay KA, Hu H, Bye PT, Elkins MR, Grimwood K, et al. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J Clin Microbiol. 2009;47(5):1503-9.
Traglia GM, Almuzara M, Merkier AK, Adams C, Galanternik L, Vay C, et al. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer. Curr Microbiol. 2012;65(6):673-8.
Nicolosi D, Nicolosi VM, Cappellani A, Nicoletti G, Blandino G. Antibiotic susceptibility profiles of uncommon bacterial species causing severe infections in Italy. J Chemother. 2009;21(3):253-60.
Felgate H, Giannopoulos G, Sullivan MJ, Gates AJ, Clarke TA, Baggs E, et al. The impact of copper, nitrate and carbon status on the emission of nitrous oxide by two species of bacteria with biochemically distinct denitrification pathways. Environ Microbiol. 2012;14(7):1788-800.
Majumder A, Bhattacharyya K, Bhattacharyya S, Kole SC. Arsenic tolerant, arsenite-oxidising bacterial strains in the contaminated soils of West Bengal, India. Sci Total Environ. 2013;463-464: 1006-14.
Dunne Jr WM, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element sequence polymerase chain reaction. Clin Infect Dis. 1995;20(4):836-41.
Ferroni A, Sermet-Gaudelus I, Abachin E, Quesne G, Lenoir G, Berche P, et al. Useof16SrRNAgenesequencingforidentificationof nonfermenting gram negative bacilli recovered from patients attending a single cystic fibrosis center. J. Clin Microbiol. 2002;40(10):3793-7.
Knippschild M, Schmid EN, Uppenkamp M. Infection by Alcaligenes xylosoxidans subsp. xylosoxidans in neutropenic patients. Oncol. 1996;53(3):258-62.
Mandell WF, Garvey GJ, Neu HC. Achromobacter xylosoxidans bacteremia. Rev Infect Dis. 1987;9(5): 1001-5.
Saiman L, Chen Y, Tabibi S, San GP, Zhou J, Liu Z, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol. 2001;39(11):3942-5.
Kanellopoulou M, Pournaras S, Iglezos H, Skarmoutsou N, Papafrangas E, Maniatis AN. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis. 2004;23(4):336-9.
Lambiase A, Catania MR, Del Pezzo M, Rossano F, Terlizzi V, Sepe A, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2011;30(8):973-80.
Cockerill FR, Wikler MA, Alder J, Dudley MN, Eliopoulos GM, Hardy DJ et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard. 9nd ed. 2012;32(2):M07-A9.
Glupczynski Y, Hansen W, Freney J, Yourassowsky E. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents. Antimicrobial Agents Chemotherapy. 1988 Feb 1;32(2):276-8.
Kanellopoulou M, Pournaras S, Iglezos H, Skarmoutsou N, Papafrangas E, Maniatis AN. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis. 2004;23(4):336-9.
Lambiase A, Catania MR, Del Pezzo M, Rossano F, Terlizzi V, Sepe A, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2011;30(8):973-80.
